Hint mode is switched on Switch off
For swift navigation between sections

Sirnaomics

PDF download

Choose all Reset all
Download Cancel
Organization name
Sirnaomics Ltd
Country name
Hong Kong
Country of registration
Cayman Islands
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Sirnaomics Ltd is a clinical-stage ribonucleic acid (RNA) therapeutics biopharmaceutical company. The Company is engaged in discovering and developing drugs for indications with unmet medical needs and market opportunities. The Company’s product pipeline has broad therapeutic utility across market diseases including oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. T

Awards

News

04/10/2024 Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development
12/07/2024 Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
19/06/2023 Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
All organization news

Documentation

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Registration is required to get access.